Medicine and Dentistry
Patient
100%
Diagnosis
70%
Survival
52%
Pancreas Adenocarcinoma
50%
Promoter Region
37%
Isocitrate Dehydrogenase
37%
Serum
37%
Neoplasm
37%
Ganglioglioma
30%
Gene
30%
Proportional Hazards Model
27%
Biological Marker
24%
Glioblastoma
22%
Inpatient
20%
Therapeutic Procedure
18%
Gemcitabine
17%
Overall Survival
14%
Log Rank Test
12%
Marker
12%
Methylation
11%
Pancreatic Ductal Adenocarcinoma
9%
Age
8%
Cells
8%
Plasma
8%
Telomerase Reverse Transcriptase
7%
Chromosome 10
7%
Chromosome 7
7%
Oligoastrocytoma
7%
Kaplan Meier Method
7%
Epidermal Growth Factor Receptor
7%
Fluorescence in Situ Hybridization
7%
Follow up
7%
Regression Analysis
7%
Immunohistochemistry
7%
Molecular Marker
7%
Mutant
7%
Disease Course
7%
Hospital
7%
Plasma Cell
6%
APC
6%
Osteogenin
6%
Diagnostic Testing
6%
Polymerase Chain Reaction
5%
Blood
5%
Biochemistry, Genetics and Molecular Biology
Survival
52%
Isocitrate Dehydrogenase
37%
Promoter Region
37%
Nested Gene
30%
Next Generation Sequencing
22%
Polymerase Chain Reaction
18%
Gemcitabine
17%
Sample
15%
Overall Survival
14%
Methylation
11%
Age
8%
Mutation
7%
Fluorescence in Situ Hybridization
7%
Survival Rate
7%
Chromosome 10
7%
Telomerase Reverse Transcriptase
7%
Epidermal Growth Factor Receptor
7%
Chromosome 7
7%
Sample Size
7%
Time
7%
Mutant
7%
Plasma Cell
6%
Sodium Bisulfite
5%
Polymerase Chain Reaction
5%
Pharmacology, Toxicology and Pharmaceutical Science
Survival
52%
Pancreas Adenocarcinoma
50%
Neoplasm
37%
Glioma
30%
Biological Marker
24%
Glioblastoma
22%
Chronic Pancreatitis
18%
DNA
17%
Gemcitabine
17%
Overall Survival
14%
Molecular Marker
7%
Disease Course
7%
Epidermal Growth Factor Receptor
7%
Osteogenin
6%
APC
6%
Bisulfite
5%